The impact of cytomegalovirus disease and asymptomatic infection on acute renal allograft rejection

Journal of Clinical Virology

Volumn 36, Issue 2, 2006, Pages 146-151

  Reischig, Tomáš ^a   Jindra, Pavel ^a   Švecová, Miroslava ^a   Kormunda, Stanislav ^a   Opatrný Jr , Karel ^a   Třeška, Vladislav ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Cytomegalovirus; Ganciclovir; Rejection; Renal transplantation; Valacyclovir

Indexed keywords

GANCICLOVIR; VALACICLOVIR;

ADULT; ARTICLE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; FEMALE; GRAFT RECIPIENT; HUMAN; HUMAN TISSUE; INFECTION RISK; KIDNEY ALLOGRAFT REJECTION; KIDNEY BIOPSY; KIDNEY DONOR; KIDNEY GRAFT; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS OF COVARIANCE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; TIME SERIES ANALYSIS; TREATMENT DURATION; VIRUS ACTIVATION;

ACUTE DISEASE; ACYCLOVIR; ANTIVIRAL AGENTS; CARRIER STATE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; GANCICLOVIR; GRAFT REJECTION; HUMANS; INCIDENCE; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME; VALINE;

EID: 33646427185     PISSN: 13866532     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcv.2006.01.015     Document Type: Article

References (21)

1. Brennan D.C., Garlock K.A., Lippmann B.J., Buller R.S., Gaudreault-Keener M., Lowell J.A., et al. Control of cytomegalovirus-associated morbidity in renal transplant patients using intensive monitoring and either preemptive or deferred therapy. J Am Soc Nephrol 8 (1996) 118-125
2. Brennan D.C., Garlock K.A., Singer G.G., Schnitzler M.A., Lippmann B.J., Buller R.S., et al. Prophylactic oral ganciclovir compared with deferred therapy for control of cytomegalovirus in renal transplant recipients. Transplantation 64 (1997) 1843-1846
3. Borchers A.T., Perez R., Kaysen G., Ansari A.A., and Gershwin M.E. Role of cytomegalovirus infection in allograft rejection: a review of possible mechanisms. Transplant Immunol 7 (1999) 75-82
4. Dickenmann M.J., Cathomas G., Steiger J., Mihatsch M.J., Thiel G., and Tamm M. Cytomegalovirus infection and graft rejection in renal transplantation. Transplantation 71 (2001) 764-767
5. Emery V.C., Sabin C.A., Cope A.V., Gor D., Hassan-Walker A.F., and Griffiths P.D. Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation. Lancet 355 (2000) 2032-2036
6. Hodson E.M., Jones C.A., Webster A.C., Stripolini G.F.M., Barclay P.G., Kable K., et al. Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: a systemic review of randomised trials. Lancet 365 (2005) 2105-2115
7. Lautenschlager I. Cytomegalovirus and solid organ transplantation: an update. Curr Opin Organ Transplant 8 (2003) 269-275
8. Ljungman P., Griffiths P., and Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 34 (2002) 1094-1097
9. Lowance D., Neumayer H.H., Legendre C.M., Squifflet J.P., Kovarik J., Brennan P.J., et al. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. N Engl J Med 340 (1999) 1462-1470
10. Meier-Kriesche H.U., Schold J.D., Srinivas T.R., and Kaplan B. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 4 (2004) 378-383
11. Metzger R.A., Delmonico F.L., Feng S., Port F.K., Wynn J.J., and Merion R.M. Expanded criteria donors for kidney transplantation. Am J Transplant 3 Suppl. 4 (2003) 114-125
12. Nett P.C., Heisey D.M., Fernandez L.A., Sollinger H.W., and Pirsch J.D. Association of cytomegalovirus disease and acute rejection with graft loss in kidney transplantation. Transplantation 78 (2004) 1036-1041
13. Nordoy I., Muller F., Nordall K.P., Rollag H., Aukrust P., and Froland S.S. Chemokines and soluble adhesion molecules in renal transplant recipients with cytomegalovirus infection. Clin Exp Immunol 120 (2000) 333-337
14. Opeltz G., Doehler B., and Ruhenstroth A. Cytomegalovirus prophylaxis and graft outcome in solid organ transplantation: a Collaborative Transplant Study report. Am J Transplant 4 (2004) 928-936
15. Paya C., Humar A., Dominguez E., Washburn K., Blumberg E., Alexander B., et al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 4 (2004) 611-620
16. Piiparinen H., Hockerstedt K., Gronhagen-Riska C., and Lautenschlager I. Comparison of two quantitative CMV PCR tests, Cobas Amplicor CMV Monitor and TaqMan assay, and pp65-antigenemia assay in the determination of viral loads from peripheral blood of organ transplant patients. J Clin Virol 30 (2004) 258-266
17. Racusen L.C., Solez K., Colvin R.B., Bonsib S.M., Castro M.C., Cavallo T., et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 55 (1999) 713-723
18. Reinke P., Prosch S., Kern F., and Volk H.D. Mechanisms of human cytomegalovirus (HCMV) (re)activation and its impact on organ transplant patients. Transplant Infect Dis 1 (1999) 157-164
19. Reischig T., Jindra P., Mares J., Cechura M., Svecova M., Hes O., et al. Valacyclovir for cytomegalovirus prophylaxis reduces the risk of acute renal allograft rejection. Transplantation 79 (2005) 317-324
20. Sagedal S., Nordal K.P., Hartmann A., Sund S., Scott H., Degre M., et al. The impact of cytomegalovirus infection and disease on rejection episodes in renal allograft recipients. Am J Transplant 2 (2002) 850-856
21. Toupance O., Bouedjoro-Camus M.C., Carquin J., Novella J.L., Lavaud S., Wynckel A., et al. Cytomegalovirus-related disease and risk of acute rejection in renal transplant recipients: a cohort study with case-control analyses. Transplant Int 13 (2000) 413-419